AYBINTIO

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland, United Kingdom

Active ingredients

The drug AYBINTIO contains one active pharmaceutical ingredient (API):

1 Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth. Read about Bevacizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AYBINTIO Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FG01	Bevacizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1826153, 1826164
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1201454001
Country: FR	Base de données publique des médicaments	Identifier(s): 65303582
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 390142, 390157
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091011, 1091012
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100439365